Works in Cancer Chemotherapy & Pharmacology, 2009, Vol 63, Issue 3

Results: 30

Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand.

Published in:

2009

By:

Gourdeau, Henriette;
McAlpine, James;
Ranger, Maxime;
Simard, Bryan;
Berger, Francois;
Beaudry, Francis;
Farnet, Chris;
Falardeau, Pierre

Publication type:

Correction Notice

Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias.

Published in:

2009

By:

Marangon, Elena;
Citterio, Marco;
Sala, Federica;
Barisone, Elena;
Lippi, Alma Augusta;
Rizzari, Carmelo;
Biondi, Andrea;
D'Incalci, Maurizio;
Zucchetti, Massimo

Publication type:

Letter

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.

Published in:

2009

By:

Fracasso PM;
Picus J;
Wildi JD;
Goodner SA;
Creekmore AN;
Gao F;
Govindan R;
Ellis MJ;
Tan BR;
Linette GP;
Fu CJ;
Pentikis HS;
Zumbrun SC;
Egorin MJ;
Bellet RE

Publication type:

Journal Article

A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 477, doi. 10.1007/s00280-008-0761-3

By:

O'Bryant, C.;
Lieu, C. H.;
Leong, S.;
Boinpally, R.;
Basche, M.;
Gore, L.;
Leonardi, K.;
Schultz, M. K.;
Hariharan, S.;
Chow, L.;
Diab, S.;
Gibbs, A.;
Eckhardt, S. G.

Publication type:

Article

A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.

Published in:

2009

By:

Kathman SJ;
Williams DH;
Hodge JP;
Dar M

Publication type:

Journal Article

Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

Published in:

2009

By:

Kalender ME;
Sevinc A;
Yilmaz M;
Ozsarac C;
Camci C

Publication type:

Journal Article

A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 469, doi. 10.1007/s00280-008-0760-4

By:

Kathman, Steven J.;
Williams, Daphne H.;
Hodge, Jeffrey P.;
Dar, Mohammed

Publication type:

Article

Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.

Published in:

2009

By:

Lemaire M;
Momparler LF;
Raynal NJ;
Bernstein ML;
Momparler RL;
Lemaire, Maryse;
Momparler, Louise F;
Raynal, Noël J-M;
Bernstein, Mark L;
Momparler, Richard L

Publication type:

journal article

Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 535, doi. 10.1007/s00280-008-0836-1

By:

Hee Man Kim;
Seungmin Bang;
Jeong Youp Park;
Jinsil Seong;
Si Young Song;
Jae Bock Chung;
Seung Woo Park

Publication type:

Article

Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 427, doi. 10.1007/s00280-008-0752-4

By:

Hyo Jin Lee;
Do Yeun Cho;
Ji Chan Park;
Sang Byung Bae;
Kyu Taek Lee;
In Sung Cho;
Chang Soon Han;
Suk Young Park;
Hwan Jung Yun;
Samyong Kim

Publication type:

Article

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 441, doi. 10.1007/s00280-008-0754-2

By:

Krishnamurthi, Smitha S.;
Brell, Joanna M.;
Hoppel, Charles L.;
Egorin, Merrill J.;
Weaver, Karen C.;
Xiaolin Li;
Ingalls, Stephen;
Zuhowski, Eleanor T.;
Schluchter, Mark D.;
Dowlati, Afshin;
Cooney, Matthew M.;
Gibbons, Joseph;
Overmoyer, Beth A.;
Ivy, S. Percy;
Remick, Scot C.

Publication type:

Article

Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 555, doi. 10.1007/s00280-008-0786-7

By:

Kalender, Mehmet;
Sevinc, Alper;
Yilmaz, Mustafa;
Ozsarac, Coskun;
Camci, Celalettin

Publication type:

Article

Pathologic complete response after palliative 3rd line chemotherapy with capecitabine alone in metastatic colorectal cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 549, doi. 10.1007/s00280-008-0766-y

By:

Hyeon Jin Cho;
Su-Jung Kim;
Sun Young Kim;
Hye-Suk Han;
Yong Sang Hong;
Seong Hoon Kim;
Seok-Byung Lim;
Kyung Hae Jung;
Hee Jin Chang;
Eun Kyung Hong

Publication type:

Article

Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 501, doi. 10.1007/s00280-008-0765-z

By:

Okabayashi, Koji;
Hasegawa, Hirotoshi;
Ishii, Yoshiyuki;
Endo, Takashi;
Ochiai, Hiroki;
Kubota, Tetsuro;
Kitagawa, Yuko

Publication type:

Article

Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 411, doi. 10.1007/s00280-008-0750-6

By:

Lemaire, Maryse;
Momparler, Louise F.;
Raynal, Noël J.-M.;
Bernstein, Mark L.;
Momparler, Richard L.

Publication type:

Article

Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 517, doi. 10.1007/s00280-008-0769-8

By:

Younis, Islam R.;
Malone, Samuel;
Friedman, Henry S.;
Schaaf, Larry J.;
Petros, William P.

Publication type:

Article

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 451, doi. 10.1007/s00280-008-0756-0

By:

Fracasso, Paula M.;
Picus, Joel;
Wildi, Jonathan D.;
Goodner, Sherry A.;
Creekmore, Allison N.;
Feng Gao;
Govindan, Ramaswamy;
Ellis, Matthew J.;
Tan, Benjamin R.;
Linette, Gerald P.;
Fu, ChauHwei J.;
Pentikis, Helen S.;
Zumbrun, Stephen C.;
Egorin, Merrill J.;
Bellet, Robert E.

Publication type:

Article

A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 391, doi. 10.1007/s00280-008-0748-0

By:

Woodahl, Erica l.;
Wang, Joanne;
Heimfeld, Shelly;
Sandmaier, Brenda M.;
O'Donnell, Paul V.;
Phillips, Brian;
Risler, Linda;
Blough, David K.;
McCune, Jeannine S.

Publication type:

Article

Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 403, doi. 10.1007/s00280-008-0749-z

By:

Feliu, Jaime;
Firvida, Jose Luis;
Castro, Javier;
Madroñal, Catherina;
Rodríguez-Jaráiz, Angeles;
Salgado, Mercedes;
Belda-Iniesta, Cristóbal;
Casado, Enrique;
García-Mata, Jesús;
González-Barón, Manuel

Publication type:

Article

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 417, doi. 10.1007/s00280-008-0751-5

By:

Awada, Ahmad A.;
Piccart, Martine J.;
Jones, Suzanne F.;
Peck, Ronald A.;
Gil, Thierry;
Lebwohl, David;
Chi-Yuan Wu;
Burris III, Howard A.

Publication type:

Article

Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 433, doi. 10.1007/s00280-008-0753-3

By:

Hee Yeon Seo;
Dae Sik Kim;
Yoon Seok Choi;
Hwa Jung Sung;
Kyong Hwa Park;
In Keun Choi;
Seok Jin Kim;
Sang Cheul Oh;
Jae Hong Seo;
Chul Won Choi;
Byung Soo Kim;
Sang Won Shin;
Yeul Hong Kim;
Jun Suk Kim

Publication type:

Article

ASNA1, an ATPase targeting tail-anchored proteins, regulates melanoma cell growth and sensitivity to cisplatin and arsenite.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 491, doi. 10.1007/s00280-008-0762-2

By:

Hemmingsson, O.;
Zhang, Y.;
Still, M.;
Naredi, P.

Publication type:

Article

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 543, doi. 10.1007/s00280-008-0758-y

By:

Ekhart, Corine;
Rodenhuis, Sjoerd;
Beijnen, Jos H.;
Huitema, Alwin D. R.

Publication type:

Article

Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 459, doi. 10.1007/s00280-008-0759-x

By:

Ju Hyun Shim;
Joong-Won Park;
Byung Ho Nam;
Woo Jin Lee;
Chang-Min Kim

Publication type:

Article

Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 509, doi. 10.1007/s00280-008-0768-9

By:

Dae Young Zang;
Dae Hyun Yang;
Hae Wan Lee;
Se Won Hwang;
Hun Ho Song;
Joo Young Jung;
Jung Hye Kwon;
Hyo Jung Kim;
Jung Han Kim;
Sa Rah Park;
Min-Jeong Kim;
Kyung Mi Jang;
Choong Kee Park;
Jong Hyeok Kim;
Bong Hwa Lee

Publication type:

Article

Effect of antacid on imatinib absorption.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 525, doi. 10.1007/s00280-008-0778-7

By:

Sparano, Brian A.;
Egorin, Merrill J.;
Parise, Robert A.;
Walters, Jennifer;
Komazec, Kristin A.;
Redner, Robert L.;
Beumer, Jan H.

Publication type:

Article

Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 381, doi. 10.1007/s00280-008-0747-1

By:

Erlich, Rafael B.;
Rickwood, Danny;
Coman, William B.;
Saunders, Nicholas A.;
Guminski, Alexander

Publication type:

Article

MDA-MB-435 cells are from melanoma, not from breast cancer.

Published in:

2009

By:

Lacroix, Marc

Publication type:

Letter

Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 3, p. 529, doi. 10.1007/s00280-008-0822-7

By:

Yoon Jae Kim;
Seungmin Bang;
Jeong Youp Park;
Seung Woo Park;
Jae Bock Chung;
Si Young Song

Publication type:

Article

Detection of complete response to imatinib mesylate (Glivec®/Gleevec®) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

Published in:

2009

By:

Kalender, Mehmet;
Sevinc, Alper;
Yilmaz, Mustafa;
Ozsarac, Coskun;
Camci, Celalettin

Publication type:

Correction Notice

Works in Cancer Chemotherapy & Pharmacology, 2009, Vol 63, Issue 3

Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand.

Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias.

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin, in resistant solid tumor malignancies.

A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state.

A Bayesian population PK-PD model for ispinesib/docetaxel combination-induced myelosuppression.

Detection of complete response to imatinib mesylate (Glivec/Gleevec) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

A Bayesian population PK–PD model for ispinesib/docetaxel combination-induced myelosuppression.

Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine.

Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer.

Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer.

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

Detection of complete response to imatinib mesylate (Glivec<sup>®</sup>/Gleevec<sup>®</sup>) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.

Pathologic complete response after palliative 3rd line chemotherapy with capecitabine alone in metastatic colorectal cancer.

Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.

Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2′-deoxycytidine.

Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma.

Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin<sup>®</sup>, in resistant solid tumor malignancies.

A novel phenotypic method to determine fludarabine triphosphate accumulation in T-lymphocytes from hematopoietic cell transplantation patients.

Combination therapy with docetaxel and low dose of cisplatin in elderly patients with advanced non-small cell lung cancer: multicenter phase II study.

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.

Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.

ASNA1, an ATPase targeting tail-anchored proteins, regulates melanoma cell growth and sensitivity to cisplatin and arsenite.

Carbamazepine induces bioactivation of cyclophosphamide and thiotepa.

Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.

Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.

Effect of antacid on imatinib absorption.

Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas.

MDA-MB-435 cells are from melanoma, not from breast cancer.

Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.

Detection of complete response to imatinib mesylate (Glivec<sup>®</sup>/Gleevec<sup>®</sup>) with 18F-FDG PET/CT for low-grade endometrial stromal sarcoma.